Literature DB >> 31135837

Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019.

Stacie B Dusetzina1, Haiden A Huskamp2, Nancy L Keating2.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31135837      PMCID： PMC6547115          DOI： 10.1001/jama.2019.4492

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  29 in total

1.  Weighing Costs and Benefits in the Economics of Cancer Care.

Authors:  Scott D Ramsey; Stacie B Dusetzina
Journal:  J Clin Oncol       Date:  2019-12-05       Impact factor: 44.544

Review 2.  Understanding Financial Hardship Among Cancer Survivors in the United States: Strategies for Prevention and Mitigation.

Authors:  K Robin Yabroff; Cathy Bradley; Ya-Chen Tina Shih
Journal:  J Clin Oncol       Date:  2019-12-05       Impact factor: 44.544

Review 3.  Impact of Pharmacy Benefit Managers on Oncology Practices and Patients.

Authors:  Trevor J Royce; Caroline Schenkel; Kelsey Kirkwood; Laura Levit; Kathryn Levit; Sheetal Kircher
Journal:  JCO Oncol Pract       Date:  2020-04-20

4.  Financial Toxicity Interventions in Hematologic Malignancies Are Timely and Necessary.

Authors:  Christopher T Su
Journal:  JCO Oncol Pract       Date:  2022-07-08

5.  The Association Between Medicare Low-Income Subsidy and Anticancer Treatment Uptake in Advanced Lung Cancer.

Authors:  Yi-Ting Chou; Joel F Farley; Thomas E Stinchcombe; Amber E Proctor; Jennifer Elston Lafata; Stacie B Dusetzina
Journal:  J Natl Cancer Inst       Date:  2020-06-01       Impact factor: 13.506

6.  Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients With Blood Cancers.

Authors:  Stacie B Dusetzina; Haiden A Huskamp; Shelley A Jazowski; Aaron N Winn; William A Wood; Adam Olszewski; Ethan Basch; Nancy L Keating
Journal:  J Natl Cancer Inst       Date:  2020-10-01       Impact factor: 13.506

7.  The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?

Authors:  Whitney N Goldsberry; Sarah S Summerlin; Allison Guyton; Brittani Caddell; Warner K Huh; Kenneth H Kim; Margaret I Liang
Journal:  Gynecol Oncol       Date:  2021-01-04       Impact factor: 5.482

8.  Out-of-Pocket Costs for Tyrosine Kinase Inhibitors and Patient Outcomes in EGFR- and ALK-Positive Advanced Non-Small-Cell Lung Cancer.

Authors:  Bernardo H L Goulart; Joseph M Unger; Shasank Chennupati; Catherine R Fedorenko; Scott D Ramsey
Journal:  JCO Oncol Pract       Date:  2020-12-07

9.  Spending and Out-of-Pocket Prices for Brand-Name Drugs Among Commercially Insured Individuals in Massachusetts, 2015-2017.

Authors:  Micah B Aaron; Anna D Sinaiko
Journal:  JAMA Netw Open       Date:  2021-03-01

10.  Outpatient oral anticancer agent utilization and costs in Manitoba from 2003 to 2016: a population-based study.

Authors:  Christine Leong; Piotr Czaykowski; Marc Geirnaert; Alan Katz; Roxana Dragan; Marina Yogendran; Colette Raymond
Journal:  Can J Public Health       Date:  2021-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.